KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2025)

Historic Assets Average for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to $2.3 billion.

  • CRISPR Therapeutics AG's Assets Average rose 27.54% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.3 billion, marking a year-over-year increase of 27.54%. This contributed to the annual value of $2.3 billion for FY2025, which is 79.77% up from last year.
  • CRISPR Therapeutics AG's Assets Average amounted to $2.3 billion in Q4 2025, which was up 27.54% from $2.1 billion recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Assets Average peaked at $2.9 billion during Q3 2021, and registered a low of $1.9 billion during Q1 2021.
  • Its 5-year average for Assets Average is $2.3 billion, with a median of $2.3 billion in 2024.
  • In the last 5 years, CRISPR Therapeutics AG's Assets Average skyrocketed by 13650.57% in 2021 and then crashed by 1753.25% in 2022.
  • CRISPR Therapeutics AG's Assets Average (Quarter) stood at $2.8 billion in 2021, then decreased by 17.53% to $2.3 billion in 2022, then fell by 6.09% to $2.2 billion in 2023, then rose by 4.21% to $2.2 billion in 2024, then grew by 0.28% to $2.3 billion in 2025.
  • Its Assets Average stands at $2.3 billion for Q4 2025, versus $2.1 billion for Q3 2025 and $2.1 billion for Q2 2025.